|Year : 2011 | Volume
| Issue : 1 | Page : 17-22
Preliminary experience with dexmedetomidine in neonatal anesthesia
÷zcengiz Dilek, GŁnes Yasemin, Mustafa ATCI
Department of Anaesthesiology, «ukurova University Faculty of Medicine , Adana, Turkey
|Date of Web Publication||11-Feb-2011|
Department of Anaesthesiology, «ukurova University Faculty of Medicine , Adana
Source of Support: None, Conflict of Interest: None
| Abstract|| |
Background: In paediatric patients dexmedetomidine has been reported to be effective in various clinical settings including provision of sedation during mechanical ventilation, prevention of emergence delirium after general anaesthesia, sedation during non invasive radiological procedures. However very few data of its use in newborn is available.
Patients & Methods: Sixteen new born patients of age 2-28 days were studied. Anaesthesia was induced with 1 mgkg -1 ketamine intravenously. Dexmedetomicline 1 μgkg -1 was infused within ten minutres. Maintenance infusion was started as 0.5-0.8 μg kg -1 h -1 until the end of surgery ortrcheel intubation was done all patients were mechanical ventelated with O2+H2O safberane 0.1-0.2%. Non invasive systolic & chastake blood pressure, heart rate, SPO2 , DETCO2 , inhated & end trial sevophrame conc and body temperature were monitored.
Results: No significant difference was observed in the measured values of haemodynamic parameter at different intervals and the base line values. No patient had hypotension bradycardia hypertension hypoxia or respiratory depression. Patients had mild hypothermia during post-operative period.
Conclusion: Dexmedetomidine 1 μgkg -1 followed by maintenance dose of 0.5 μg kg -1 h -1 as an adjacent to sevoflurane anaesthesia in new born undergoing laparatomy provides haemodynamic stability during heightened surgical stimulate.
Keywords: Dexmedetomidine, Neonatal anesthesia
|How to cite this article:|
Dilek ÷, Yasemin G, ATCI M. Preliminary experience with dexmedetomidine in neonatal anesthesia. J Anaesthesiol Clin Pharmacol 2011;27:17-22
|How to cite this URL:|
Dilek ÷, Yasemin G, ATCI M. Preliminary experience with dexmedetomidine in neonatal anesthesia. J Anaesthesiol Clin Pharmacol [serial online] 2011 [cited 2020 Jul 10];27:17-22. Available from: http://www.joacp.org/text.asp?2011/27/1/17/76610
Dexmedetomidine is a selective and potent a2-adrenoceptor agonist, with hypnotic, analgesic and sympatholytic properties.  In surgical patients, it reduces the use of other anesthetics, minimizes sympathetic response to nociceptive stimuli and improves intraoperative hemodynamic stability. 
In contrast with many anesthetic agents, dexmedetomidine preserves spontaneous ventilation. This property makes dexmedetomidine a useful adjuvant to general anesthesia during procedures requiring spontaneous ventilation, such as upper airway surgery and manipulation.  One case report described administering dexmedetomidine as the only anesthetic for three adults needing upper airway operations.  Also Shukry et al  reported that dexmedetomidine was useful anesthetic agent in childrens anesthesia. In the pediatric population, dexmedetomidine has been reported effective in various clinical scenarios, including the provision of sedation during mechanical ventilation, prevention of emergence delirium after general anesthesia, procedural sedation during noninvasive radiologic procedures, including magnetic resonance imaging, and in the control of withdrawal after the prolonged use of opioids and benzodiazepines. ,,,,,,,,
But, there are very few data related to dexmedetomidine in newborn patients.
This study aimed to assess hemodynamic responses to nociceptive stimuli when dexmedetomidine is used as an adjuvant anesthetic to sevoflurane in newborn patients submitted to surgery for laparotomy.
| Patients and Methods|| |
We prospectively studied the charts of full term neonates (born at 37 weeks of gestation or more, and less than 29 days old), who underwent general anesthesia, using dexmedetomidine and sevoflurane, for abdominal surgical procedures in the pediatric operating theatre of a University Hospital between October 2008 and March 2009.
The Ethics Committee of our institution approved the study and informed consent was obtained from the parents of all selected subjects. Exclusion criteria were the presence of major congenital malformations, birth weight <1000 g, previous or concurrent use of opioid for any reason (cesarean section with general anesthesia), hemodynamic instability before the indication of tracheal intubation and refusal of the parents to enroll the neonate in the study.
Twenty newborns were studied, but four patients excluded due to deep bradycardia. These patients were given atropin sulphate 40 μg kg -1 . After this observation, we changed the study protocol and anesthesia was induced 1 mg kg -1 ketamine in all neonates. Dexmedetomidine (1 μg kg -1 ) was infused during 10 minutes and maintenance infusion was obtained with dexmedetomidine (0.5-0.8 μg kg - 1 h - 1) until the end of surgery. Cardiorespiratory monitoring included noninvasive blood pressure, [sistolic arterial pressure (SAP), diastolic arterial pressure (DAP)], electrocardiogram and heart rate (HR), peripheral oxygen saturation (SpO2), exhaled carbondioxide (PETCO2), inhaled and end-tidal sevoflurane concentrations. Body temperature was monitored by an esophageal thermometer. Patients were intubated (oro-tracheal intubation) and mechanically ventilated with 65% N2O in 35% O2 during the anesthesia. Sevoflurane was administered 0.1 - 0.2 %. Mechanical ventilation was adapted to maintain an end-tidal CO2 level of 33-36 mmHg and SpO2 in the range of 95-100%. We recorded measurements of hemodynamic parameters during the anesthesia. These data were assessed before anesthesia induction and maintained every 5 min during the operation time.
Adjustments were predefined to prevent hypotension and low cardiac output, as well as to provide adequate analgesia.
- If systolic blood pressure decreased (equal to or greater than 20% of baseline levels) infusion solution was infused for 5 minutes and repeated up to three times, if hypotension persisted;
- If systolic blood pressure decreased (equal to or greater than 30% of baseline levels) dexmedetomidine infusion was reduced by 50%. If blood pressure levels did not reach at least 20% of baseline levels, intravenous administration of dexmedetomidine was discontinued.
- If the heart rate decreased more than 30% from baseline levels, a dose of 20 μg kg -1 intravenous atropine was administered.
- If systolic blood pressure and/or heart rate increased more than 20% from baseline levels, ketamine(1mg -1 kg -1 ) was given at five-minute intervals. If systolic blood pressure and/or heart rate stil increased more than 20% from baseline levels, anesthesia was maintained with sevoflurane 1-2 %. The endpoint was a maximal acceptable increment of 20% from baseline levels.
To evaluate the efficacy of the anesthesia regimen, the need for supplemental doses of ketamine or changes in the dexmedetomidine infusion rate were noted. Additional doses of ketamine (1mg -1 kg -1 ) were administered only if the analgesia was inadequate and bradycardia present. Anesthesia was discontinued after finished operation. The trachea was extubated on resumption of spontaneous respiration and control of the airway. Time to extubation was recorded in neonates. Extubation time is 7defined that skin suturation was finished to spontanous respiration. All the newborns was heated externally using a blanket.
Statistical analysis was performed using SPSS version 11.0 software (SPSS Inc., Chicago, IL). DBP, SBP, HR and body temparature were compared using two-way repeated measures analysis of variance (ANOVA). All data were compared to baseline values. We accepted the baseline values as preoperative measurements. Unless otherwise specified, data are mean±SD, and p value <0.05 was defined as significance.
| Results|| |
The cohort for the study included 16 newborn patients ranging in age from 2 to 28 days old (mean, 15.13 ± 14.93 days) and in weight from 1600 to 5300 g (3151,25 ± 954,93 g). Ten patients had intestinal atresia and six patients had intraabdominal tumors. The duration of operation was 2,3 ± 0,9 hours.
No significant differences were observed measurement intervals compared to the baseline levels in DBP, SBP and HR. Three patients needed supplemantal ketamine doses only once. Sevoflurane concentration was 0.16±0.05 %. No patient needed more than 0.2 % sevoflurane concentration. Comparing to the baseline values a remarkable decrease in temperature at all the observation times was not statistical significant. (p>0.05). Mean effective dose was 0.5 μg -1 kg - 1 h -1 . This dose obtained hemodynamic stability and effective anesthesia.
The duration of extubation was 16.1±3.9 minutes (min=10, max=23 min). All the patients were extubated in the operation room and patients' breathing was satisfactory. After extubation the patients cried and opened the eyes.
No patients had any hypotension, hypertension, bradycardia, hypoxia and respiratory depression. The patients had mild hypotermia during the postoperative period. External heating was very difficult, however we did not observe any complication related to hypotermia.
| Discussion|| |
In this study, dexmedetomidine with ketamine induction obtained very stable hemodynamic effect and very comfortable anesthesia in newborn anesthesia. Smania et al. 5 reported that in their study, infusion of 0.5 μg -1 kg -1 h -1 of dexmedetomidine as isoflurane adjuvant at 1.2% allowed control of the hemodynamic response to stimuli with values equal to or less than those of the baselines, reflecting adequate control of the sympathetic stimulus in videolaparoscopic appendectomy. Some studies have described a remarkable decrease in the MAC of isoflurane, with lessening of consumption, when combined with the continuous infusion of dexmedetomidine, in plasma concentrations of 0.3 and 0.6 ng ml- 1., Munro et al.  reported their experience with dexmedetomidine as the primary agent for sedation during cardiac catheterization in infants and children. The average maintenance infusion rate was 1.15±0.29 1g -1 kg -1 per hour (range, 0.6-2.0 i g -1 kg -1 per hour). Tosun et al.  compared dexmedetomidine and ketamine with propofol and ketamine in 44 children (age range, 4 months to 16 years) with acyanotic congenital heart disease undergoing cardiac catheterization. Ketamine (1 mg -1 kg -1 ) and dexmedetomidine (1 1 g -1 kg -1 ) were administered over 10 minutes followed by an infusion at 0.7 1g -1 kg -1 per hour of dexmedetomidine and 1 mg -1 kg -1 per hour of ketamine. K11roglu et al.  compared dexmedetomidine and propofol for sedation of children undergoing magnetic resonance imaging. The patients were taken to dexmedetomidine (1 1 g -1 kg -1 followed by an infusion of 0.5 1 g -1 kg -1 per hour) and patients sedation was very effective. In current study, we observed that dexmedetomidine with very low sevoflurane concentration obtained very smooth anesthesia with stable hemodynamic effect. Also anesthesia was enough to surgery, there were no response for surgical stimulation.
Mester et al.  found that once the invasive/painful component of the procedure was completed, effective sedation could be provided by the dexmedetomidine infusion alone. In their study cohort, supplemental ketamine was required in only three patients (two patients when there was a need to change out the cannulae and in one other patient approximately 10 minutes after decreasing the dexmedetomidine infusion from 2 to 1 1 g -1 kg -1 per hour). These results supported our findings, however our three patients needed supplamentary ketamine dose only ones.
Suppression of hemodynamic response to nociceptive stimuli, with concomitant reduction of hormone release, is one of the major goals of an adequate "anesthetic state."  Blood pressure and heart rate are the hemodynamic variables habitually used to assess the adequate block of the response to surgical stimulation. , Similarly to what happens in adult patients, it was observed that during tracheal intubation dexmedetomidine induces lower increases of blood pressure levels and of the heart rate when compared to the placebo. ,
Vilo et al.  reported that the pharmacokinetics of dexmedetomidine were clearly dependent on subject age in this study. Total plasma clearance was similar in younger and older children, but the volume of distribution (Vss) and consequently also the terminal elimination half-life (t½,z) were greater in children younger than 2 yr of age compared with older children. There was, however, quite marked inter≠individual variation in the pharmacokinetic parameters, especially in the younger age group. There is less experience reported for use of dexmedetomidine in infants, but in a recent larger study that included infants and neonates we found similar results with respect to respiratory depression.  Others have used dexmedetomidine for direct laryngoscopy and bronchoscopy in a small group of spontaneously breathing infants, as well as for cardiac catheterization in infants as young as 3 months of age. , Ketamine was chosen as the agent for supplemental sedation. The reason for choosing ketamine was three-fold. First, ketamine has minimal negative effect on the systemic vascular resistance and has been shown to increase mean arterial pressure and heart rate. , This theoretically could counteract the drop in mean arterial pressure and heart rate caused by dexmedetomidine. , Second, ketamine has less negative effect on the respiratory drive when compared with opioids and benzodiazepines. Third, like with opioids and benzodiazepines dexmedetomidine has an additive effect with ketamine. , This allows for a much lower dose of ketamine needed for the same effect. A concern that many may have when using ketamine is its adverse effect of increased salivation. This is likely offset by dexmedetomidine's effect on the salivary glands causing xerostomia.  Given the relatively short duration of the procedures performed, dexmedetomidine was administered as a bolus at a rate of 0.2 1 g -1 kg -1 h -1 without a maintenance infusion. Although some literature has shown that with acute intravenous administration, increases of approximately 20% in mean arterial blood pressure can occur, this was not observed in any of their patients.  Barton et al.  reported that invasive procedures can be successfully performed in spontaneously breathing infants and toddlers with congenital heart disease using dexmedetomidine alone or in combination with low dose ketamine.
During the our study period, body temperature decreased compared to the baseline measurement. In our study, patients had no bradycardia. Probably, ketamine prevented this effect of dexmedetomidine. Finkel et al.  in a neonate, postulated that dexmedetomidine was the likely cause of hypothermia and subsequent bradycardia. Dexmedetomidine-induced bradycardia relates to its central sympatholytic action with unopposed vagal tone, reduction of noradrenaline release, or direct vagotonic effect and is usually reversed by anticholinergics.  In this patient, bradycardia was not reversed by atropine and was resolved only with correction of temperature in the continuing presence of dexmedetomidine. Dexmedetomidine affects thermogenesis by several mechanisms. In wild-type mice, dexmedetomidine causes profound hypothermia, an effect that is markedly attenuated in animals that are genetically deficient in a2-AR.  This hypothermic response is thought to result from the activation of a2-ARs in the hypothalamus, reducing metabolic heat production.  In infants, thermoregulation depends initially on vasoconstriction and increased metabolic heat production via nonshivering thermogenesis. , Therefore, given the effects of dexmedetomidine on thermo regulation, it is not surprising that dexmedetomidine caused profound hypothermia in our patients. In a setting without active warming, dexmedetomidine can cause profound hypothermia in neonates. Careful attention to temperature control and the routine use of exogenous heat sources in infants receiving dexmedetomidine are imperative.
Many drugs in anesthesia conform to multiple compartment models and the time required for the plasma drug concentration to decline by 50% after terminating infusion (context-sensitive half-time) is markedly different from the elimination half-lives. Elimination half-life may be of limited value in characterizing disposition of intravenous drugs during dosing periods relevant to anesthesia. Dexmedetomidine displays an increasing context-sensitive half-time with infusion duration because of return of drug to plasma from peripheral compartments after ceasing infusion. Potts et al.  demonstrated that there are age-related changes in the context-sensitive half-time with it taking 1.24 h for plasma dexmedetomidine concentration to decrease by half in neonates compared with 0.49 h in adults after an infusion of 1 h. These changes are attributable to clearance maturation. In our study, all the newborns can be extubated after surgery. This result has showed that dexmedetomidine obtained early recovery from anesthesia, but dexmedetomidine blood level couldn't measure in this study.
The current study, showed that an initial dose of dexmedetomidine (1 1 g -1 kg -1 ) followed by a maintenance dose of 0.5 1 g -1 kg -1 h -1 , as an adjuvant to sevoflurane anesthesia, in newborn submitted to laparotomy, kept the heart rate and blood pressure stable, also in periods of heightened surgical stimulation. Nonetheless, larger prospective studies are needed to further evaluate its efficacy and safety in this patient population.[Table 1],[Figure 1],[Figure 2],[Figure 3],[Figure 4].
|Figure 1 :Diastolic pressures of the patients during the operation (M:minutes)|
Click here to view
|Figure 2 :Systolic pressures of the patients during the operation (M:minutes)|
Click here to view
|Figure 4 :Temperature of the patients during the operation (M:minutes) rements were compared to the preoperative values|
Click here to view
| References|| |
|1.||Tobias JD. Dexmedetomidine: applications in pediatric critical care and pediatric anesthesiology. Pediatr Crit Care Med. 2007;8: 115-31. |
|2.||Belleville JP, Ward DS, Bloor BC, et al. Effects of intravenous dexmedetomidine in humans. I. Sedation, ventilation, and metabolic rate. Anesthesiology. 1992; 77: 1125-33. |
|3.||Ramsay MA, Luterman DL. Dexmedetomidine as a total intravenous anesthetic agent. Anesthesiology 2004; 101: 787-790. |
|4.||Shukry M, Kennedy K. Dexmedetomidine as a total intravenous anesthetic in infants. Pediatr Anesth 2007; 17:581-583. |
|5.||Smania MC, POva JP, GarcOa PC. Dexmedetomidine in anesthesia of children submitted to videolaparoscopic appendectomy: a double-blind, randomized and placebo-controlled study. Rev Assoc Med Bras 2008; 54: 308-13. |
|6.||Munro HM, Tirotta CF, Felix DE, et al. Initial experience with dexmedetomidine for diagnostic and interventional cardiac catheterization in children. Pediatr Anesth. 2007; 17: 109-112. |
|7.||Tosun Z, Akin A, Guler G, et al. Dexmedetomidine- ketamine and propofol-ketamine combinations for anesthesia in spontaneously breathing pediatric patients undergoing cardiac catheterization. J Cardiothorac Vasc Anesth. 2006; 20: 515-519. |
|8.||Barton KP, Munoz R, Morell VO, et al. Dexmedetomidine as the primary sedative during invasive procedures in infants and toddlers with congenital heart disease. Pediatr Crit Care Med. 2008; 9: 612-5. |
|9.||KOroglu A, Teksan H, Sagor O, et al. A comparison of the sedative, hemodynamic and respiratory effects of dexmedetomidine and propofol in children undergoing magnetic resonance imaging. Anesth Analg. 2006; 103: 63-67. |
|10.||Hamish MM, Tirotta CF, Felix DE, et al. Initial experience with dexmedetomidine for diagnostic and interventional cardiac catheterization in children. Pediatr Anesth 2007; 17: 109-112. |
|11.||Chrysostomou C, Avolio T, Orr R, et al. Dexmedetomidine use in a pediatric cardiac intensive care unit: Can we safely use it in infants after cardiac surgery? Pediatr Crit Care Med 2007; 8: A308. |
|12.||Mukhtar AM, Obayah EM, Hassona AM. The use of dexmedetomidine in pediatric cardiac surgery. Anesth Analg 2006; 103: 52-56. |
|13.||Szumita PM, Baroletti SA, Anger KE, et al. Sedation and analgesia in the intensive care unit: Evaluating the role of dexmedetomidine. Am J Health Syst Pharm 2007; 64: 37-44. |
|14.||Aantaa R, Jaakola ML, Kallio A, et al. Reduction of the minimum alveolar concentration of isoflurane by dexmedetomidine. Anesthesiology. 1997; 86: 1055-60. |
|15.||Scheinin B, Lindgren L, Randell T, et al. Dexmedetomidine attenuates sympathoadrenal responses to tracheal intubation and reduces the need for thiopentone and perioperative fentanyl. Br J Anaesth. 1992; 68: 126-31. |
|16.||Munro HM, Sleigh JW, Paxton LD: The cardiovascular response to ketamine: The effects of clonidine and lignocaine. Abstr. Acta Anaesthesiol Scand 1993; 37: 75-78 |
|17.||Mester R, Easley RB, Brady KM, et al. Monitored an≠esthesia care with a combination of ketamine and dexmedetomidine during cardiac catheterization. Am J Ther. 2008; 15: 24-30. |
|18.||Prys-Roberts C. Anaesthesia: a practical or impractical construct? Br J Anaesth. 1987; 59: 1341-5. |
|19.||Stanski D. Monitoring depth of anesthesia. In: Miller RD. Anesthesia.4th ed. Philadelphia: Churchill Livingstone; 1994. p.1127-59. |
|20.||Kaul HL, Bharti N. Monitoring depth of anaesthesia. Indian J Anaesth. 2002; 46: 323-32. |
|21.||21- Aho M, Erkola O, Kallio A, et al. Dexmedetomidine infusion for maintenance of anesthesia in patients undergoing abdominal hysterectomy. Anesth Analg. 1992; 75: 940-6. |
|22.||Vilo S, Rautiainen P, Kaisti K, et al. Pharmacokinetics of intravenous dexmedetomidine in children under 11 yr of age. Br J Anaesth. 2008; 100: 697-700. |
|23.||Oklu E, Bulutcu FS, Yalcin Y, et al. Which anesthetic agent alters the hemodynamic status during pediatric catheterization? Comparison of Propofol versus Ketamine.J Cardiothorac Vasc Anesth 2003; 17: 686-≠690. |
|24.||Petroz GC, Sikich N, James M, et al. A phase I, two≠center study of the pharmacokinetics and pharmacodynamics of dexmedetomidine in children. Anesthesiology 2006; 105: 1098-110 |
|25.||Suzuki M, Tsueda K, Lansig P, et al. Small dose ketamine enhances morphine-induced analgesia after outpatient surgery. Anesth Analg 1999; 89: 98-103 |
|26.||Scheinin H, Aantaa R, Anttila M, et al. Reversal of the sedative and sympatholytic effects of dexmedetomidine with a specific alpha2- adrenoceptor antagonist atipamezole: A pharmacodynamic and kinetic study in healthy volunteers. Abstr. Anesthesiology 1998; 89: 574≠-584 |
|27.||Dyck JB, Maze M, Haack C, et al: The pharmacokinetics and hemodynamic effects of intravenous and intramuscular dexmedetomidine hydrochloride in adult human volunteers. Anesthesiology 1993; 78: 813-820 |
|28.||Finkel JC, Quezado ZM. Hypothermia-induced bradycardia in a neonate receiving dexmedetomidine. J Clin Anesth.2007: 19; 290-292. |
|29.||Khan ZP, Ferguson CN, Jones RM. Alpha-2 and imidazoline receptor agonists. Their pharmacology and therapeutic role. Anaesthesia 1999; 54: 146-65. |
|30.||Lahdesmaki J, Sallinen J, MacDonald E, et al. Alpha2-adrenergic drug effects on brain monoamines, locomotion, and body temperature are largely abolished in mice lacking the alpha2A adrenoceptor subtype. Neuropharmacology 2003; 44: 882-92. |
|31.||Quan N, Xin L, Ungar AL, Blatteis CM. Preoptic norepinephrine induced hypothermia is mediated by alpha 2-adrenoceptors. Am J Physiol 1992; 262: R407≠11. |
|32.||Dawkins MJ, Scopes JW. Non-shivering thermogenesis and Brown adipose tissue in the human new-born infant. Nature 1965; 206: 201-2. |
|33.||Sinclair JC. Thermal control in premature infants. Annu Rev Med 1972; 23: 129-48. |
|34.||Potts AL, Warman GR, Anderson BJ. Pediatr Anesth. 2008;18:722-30. |
[Figure 1], [Figure 2], [Figure 3], [Figure 4]